TOKYO -- Japanese biotech company Takara Bio plans to mass produce novel coronavirus vaccinations as early as this year, President and CEO Koichi Nakao told Nikkei in an interview.
Takara partnered with bio company AnGes and Osaka University to develop the DNA vaccine. It will start clinical trials in the summer. If Japan's health ministry approves a production and sales license this fall, the company would be ready to supply vaccines to 200,000 people this year.
